Zomedica (ZOM) Stock Price, News & Analysis

Company Overview

Zomedica Pharmaceuticals Corp. is a veterinary health company dedicated to the development and commercialization of diagnostic and therapeutic products for companion animals. The company’s flagship offering, TRUFORMA®, is a point-of-care immunoassay platform that enables veterinarians to obtain laboratory-quality results within minutes. Initial assays launched on the TRUFORMA system include tests for thyroid and adrenal biomarkers in dogs and cats, with plans to expand the menu to address other common conditions such as chronic kidney disease and cardiac disorders.

Headquartered in Ann Arbor, Michigan, Zomedica serves veterinary practices across North America through a hybrid model of direct sales and third-party distribution partnerships. The company has invested in establishing a robust supply chain and quality control processes to support scalable manufacturing of its diagnostic cartridges. In addition to the United States, Zomedica is actively pursuing regulatory approvals and distribution agreements to enter Canadian and European veterinary markets.

Founded in 2015 and taken public in 2018 via a reverse merger transaction, Zomedica has grown from a research-focused start-up into a commercial organization with a dedicated development pipeline. Beyond diagnostics, the company is advancing therapeutic candidates aimed at addressing diseases for which there are limited treatment options in veterinary medicine. Strategic collaborations with contract research organizations and academic institutions support the discovery and validation of novel biomarkers and immunotherapies.

Zomedica’s leadership team combines expertise in human diagnostics, veterinary medicine and life sciences commercialization. Chief Executive Officer Robert Cohen brings more than 20 years of experience in diagnostic product development, while Chief Financial Officer Derek B. Down oversees corporate finance and investor relations. The company’s board of directors features industry veterans with backgrounds in veterinary practice, pharmaceutical research and global commercialization, guiding Zomedica’s mission to enhance the standard of care for companion animals.

Key Stats

• Today's Range: N/A
• 50-Day Range: $0.10 to $0.15
• 52-Week Range: N/A
• Volume: 790,936 shs
• Average Volume: 4.63 million shs
• Market Capitalization: $95.35 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Strong Buy

ZOM Stock Analysis - Frequently Asked Questions

How were Zomedica's earnings last quarter?

Zomedica Corp. (NYSEAMERICAN:ZOM) announced its quarterly earnings results on Thursday, November, 7th. The company reported ($0.01) EPS for the quarter. The firm had revenue of $7 million for the quarter. Zomedica had a negative net margin of 232.88% and a negative trailing twelve-month return on equity of 12.47%.
Read the conference call transcript.

How do I buy shares of Zomedica?

Shares of ZOM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Zomedica own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Zomedica investors own include Jumia Technologies (JMIA), Nano Dimension (NNDM), AST SpaceMobile (ASTS), NIO (NIO), Bakkt (BKKT), Phunware (PHUN) and Inuvo (INUV).

Company Calendar

• Last Earnings: 11/07/2024
• Today: 7/13/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSEAMERICAN
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NYSEAMERICAN:ZOM
• CIK: 1684144
• Web: www.zomedica.com
• Phone: 734-369-2555
• Fax: N/A
• Employees: 50
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($0.06)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$34.53 million
• Net Margins: -232.88%
• Pretax Margin: -232.24%
• Return on Equity: -12.47%
• Return on Assets: -11.84%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 10.82
• Quick Ratio: 10.15

Sales & Book Value

• Annual Sales: $25.19 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.24 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 979,950,000
• Free Float: 938,890,000
• Market Cap: $95.35 million
• Optionable: Not Optionable
• Beta: 1.03